京新药业46岁董秘洪贇飞是药剂学硕士，兼任战略发展总监、负责投资及化学研发

Core Viewpoint - Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor, focusing on innovation-driven pharmaceutical development in central nervous system and cardiovascular diseases [3]. Financial Performance - The company projects revenues of RMB 4 billion and RMB 4.16 billion for 2023 and 2024, respectively, with net profits of RMB 623 million and RMB 719 million for the same years [4]. - For the first ten months of 2025, the company reported revenues of RMB 3.34 billion, a decrease of 2.74% year-on-year, while net profit increased by 12.69% to RMB 629 million [3][4]. Business Model - Jingxin Pharmaceutical's business model combines the commercialization of existing products with the ongoing development of its product pipeline, which includes a range of pharmaceuticals, active pharmaceutical ingredients, and medical devices [3]. Shareholding Structure - The company is controlled by a group of shareholders led by Executive Director and Chairman Lv Gang, who directly holds approximately 20.77% of the company, while Jingxin Holdings and Jinzhihua Investment hold 15.68% and 51% of Jingxin Holdings, respectively [5]. Leadership - Lv Gang, aged 63, has been with the company since 1999 and has held various leadership roles, including Executive Director and General Manager, responsible for strategic planning and overall operations [9][10]. - Hong Yunfei, aged 46, joined the company in 2005 and is currently the Executive Director and Secretary of the Board, overseeing strategic investments and chemical research [11].